Sorrento Therapeutics (FRA:8STN) Other Operating Expense : €4.30 Mil (TTM As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Sorrento Therapeutics Other Operating Expense?

Sorrento Therapeutics's Other Operating Expense for the three months ended in Jun. 2023 was €1.04 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 was €4.30 Mil.

Sorrento Therapeutics's quarterly Other Operating Expense declined from Dec. 2022 (€1.07 Mil) to Mar. 2023 (€1.05 Mil) and declined from Mar. 2023 (€1.05 Mil) to Jun. 2023 (€1.04 Mil).

Sorrento Therapeutics's annual Other Operating Expense increased from Dec. 2020 (€3.33 Mil) to Dec. 2021 (€3.66 Mil) and increased from Dec. 2021 (€3.66 Mil) to Dec. 2022 (€4.08 Mil).

Sorrento Therapeutics Other Operating Expense Historical Data

The historical data trend for Sorrento Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Other Operating Expense Chart

Sorrento Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Operating Expense

Get a 7-Day Free Trial

2.65

3.55

3.33

3.66

4.08

Sorrento Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Other Operating Expense	Get a 7-Day Free Trial															0.98	1.14	1.07	1.05	1.04

Sorrento Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.30 Mil.

Sorrento Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Sorrento Therapeutics (FRA:8STN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (FRA:8STN) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

SRNEQ:USA

Address

4955 Directors Place, San Diego, CA, USA, 92121

Website

https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (FRA:8STN) Headlines

No Headlines